Review
Year 2018,
Volume: 3 Issue: 1-2, 13 - 16, 04.04.2019
Abstract
Yaygınlığı her geçen gün artan kanserin tedavisinde son yıllarda geliştirilen yöntemler ile yeni ufuklar açıldı. Özellikle “konağın bağışıklık sistemini uyararak kansere karşı güdümleme” anlamını taşıyan immünoterapinin kemoterapiden daha iyi etkinlik gösterirken daha az yan etkiye sahip olması ile gelecekte ilk sıra tedaviler arasında olması beklenmektedir. Ancak bu tedavilerin olumsuz etkileri henüz tam olarak tanımlanmamıştır. Bu derlemede, özellikle akciğer kanserinin tedavisinde kullanılan anti-programlanmış ölüm reseptörü 1 ve anti-programlanmış ölüm ligandı 1 ajanlarının beklenmedik etkisi olarak ortaya çıkan saç repigmentasyonu tartışıldı.
Keywords
Anti-programlanmış ölüm ligandı 1 anti-programlanmış ölüm reseptörü 1 kanser saç repigmentasyonu immünoterapi
References
- 1. Özlük AA, Oytun MG, Günenç D. Kanser immünoterapisi. FNG & Bilim Tıp Transplantasyon Dergisi 2017;2:22. 2. Barbaros B, Dikmen D, Kanser immünoterapisi, Erciyes Üniversitesi Fen Bilimleri Enstitüsü Dergisi 2015;31:177-81. 3. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010;37:430-9. 4. Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. A personalized view on cancer immunotherapy. Cancer Lett 2014;352:113-25. 5. Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu H, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget 2017;8:83986-94. 6. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10. 7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. 8. Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016;60:12-25. 9. Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol 2016;74:455-61. 10. Tobin DJ. Aging of the hair follicle pigmentation system. Int J Trichology 2009;1:83-93. 11. Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, et al. Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer. JAMA Dermatol 2017;153:1162-5. 12. Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, et al. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer. JAMA Dermatol 2017;153:1162-5. 13. Dasanu CA, Mitsis D, Alexandrescu DT. Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process! J Oncol Pharm Pract 2013;19:165-9. 14. Cheng YP, Chen HJ, Chiu HC. Erlotinib-induced hair repigmentation. Int J Dermatol 2014;53:55-7. 15. Tintle SJ, Dabade TS, Kalish RA, Rosmarin DM. Repigmentation of hair following adalimumab therapy. Dermatol Online J 2015;21. pii: 13030/qt6fn0t1xz. 16. Nagase K, Inoue T, Narisawa Y. Manifest hair repigmentation associated with etretinate therapy. J Dermatol 2017;44:34-5. 17. Arck PC, Overall R, Spatz K, Liezman C, Handjiski B, Klapp BF, et al. Towards a “free radical theory of graying”: melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage. FASEB J 2006;20:1567-9. 18. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
Year 2018,
Volume: 3 Issue: 1-2, 13 - 16, 04.04.2019
Abstract
References
- 1. Özlük AA, Oytun MG, Günenç D. Kanser immünoterapisi. FNG & Bilim Tıp Transplantasyon Dergisi 2017;2:22. 2. Barbaros B, Dikmen D, Kanser immünoterapisi, Erciyes Üniversitesi Fen Bilimleri Enstitüsü Dergisi 2015;31:177-81. 3. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010;37:430-9. 4. Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. A personalized view on cancer immunotherapy. Cancer Lett 2014;352:113-25. 5. Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu H, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget 2017;8:83986-94. 6. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10. 7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. 8. Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016;60:12-25. 9. Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol 2016;74:455-61. 10. Tobin DJ. Aging of the hair follicle pigmentation system. Int J Trichology 2009;1:83-93. 11. Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, et al. Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer. JAMA Dermatol 2017;153:1162-5. 12. Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, et al. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer. JAMA Dermatol 2017;153:1162-5. 13. Dasanu CA, Mitsis D, Alexandrescu DT. Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process! J Oncol Pharm Pract 2013;19:165-9. 14. Cheng YP, Chen HJ, Chiu HC. Erlotinib-induced hair repigmentation. Int J Dermatol 2014;53:55-7. 15. Tintle SJ, Dabade TS, Kalish RA, Rosmarin DM. Repigmentation of hair following adalimumab therapy. Dermatol Online J 2015;21. pii: 13030/qt6fn0t1xz. 16. Nagase K, Inoue T, Narisawa Y. Manifest hair repigmentation associated with etretinate therapy. J Dermatol 2017;44:34-5. 17. Arck PC, Overall R, Spatz K, Liezman C, Handjiski B, Klapp BF, et al. Towards a “free radical theory of graying”: melanocyte apoptosis in the aging human hair follicle is an indicator of oxidative stress induced tissue damage. FASEB J 2006;20:1567-9. 18. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Derleme |
| Authors | |
| Publication Date | April 4, 2019 |
| Published in Issue | Year 2018 Volume: 3 Issue: 1-2 |
